spacer
Thinking
A front-on close-up image of human feet wearing socks and standing on a scale next to a curled-up measuring tape.

The Impact Of GLP-1 Drugs On The Food Industry

October 28, 2025

A Path For Food Brands and Restaurants

Until recently, consumers have been told there’s no such thing as a miracle weight loss drug. That moderation is the magic formula. That a balanced diet of nutritious foods, the occasional indulgence, and consistent exercise is the proven path to a healthy lifestyle.

But today, that formula is being rewritten. The global weight-loss market is projected to reach $157.54 billion by 2032,1 driven in large part by the rapid adoption of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro. What began as a medical breakthrough for diabetes management has become a cultural and commercial force, reshaping not only bodies but behaviors.

Over 8% of Americans are taking GLP-1 medications, with roughly another 35% showing interest.2 As GLP-1 use grows, early data show changes in consumer purchasing, portion sizes, and dining frequency. For food manufacturers and restaurants, these behavioral changes are set to influence everything from product innovation to menu strategy.

In this blog, we’ll look at emerging trends, explore what current statistics reveal about evolving consumption habits, and discuss how brands and operators can adapt to stay relevant in this disruptive market.

The Rise of GLP-1: A Look at the Data

The popularity of GLP-1 drugs has accelerated faster than nearly all modern pharmaceutical trends. Originally developed to manage Type 2 diabetes, these medications work by mimicking a natural hormone that regulates blood sugar and appetite.

According to an American Medical Association article, prescriptions for GLP-1s have surged more than 500%, from $13.7 billion to $71.7 billion,3 with demand showing no signs of slowing. Researchers project global sales could surpass $80 billion annually by 2030, as new entrants and formulations enter the market.4

Middle- to high-income adults in the U.S., most notably within urban and suburban areas, are the most common users of these medications. However, as generic versions and increased insurance coverage surface, usage could broaden significantly, expanding the market influence on food purchasing patterns.

Appetite Shift: How GLP-1 Is Changing Consumer Behavior

GLP-1 takers report they’re eating less, and differently. A 2024 KPMG study estimated that caloric intake dropped by 21%,5 as users sought out smaller portions while consuming more nutrient-rich food choices.

While consumption patterns change for GLP-1 recipients, grocery shopping habits are also shifting. The KPMG study revealed a 31% decrease in monthly grocery spending6, with impulse purchases for snacking and indulgent options declining during treatment. These consumers are opting for lower-sugar, higher-protein, and higher-fiber meals that stimulate that “fullness feeling.” More often, households with GLP-1 users purchase functional, clean-label, organic, and portion-controlled products over bulk frozen dinners and processed foods.

Restaurant Reality: Dining Out In The GLP-1 Era

Restaurants are feeling the effects of reduced traffic and spending, especially for quick-serve and fast-casual chains, where healthy options are limited and recipes and portion sizes need consistency across each location. The impact is notably more significant than adjusting menus for still-popular diets, i.e., keto, paleo, or Atkins. In fact, GLP-1ers spend approximately $30 less per week on restaurant meals and cut their dining frequency by more than 50%.7

For operators, the opportunity to leverage these behavioral changes lies in the willingness to adapt. Reimagining combo meals into mini versions or half-size orders, improving the nutritional value of menu items that balance flavor and function, and partnering with health organizations to certify that menu items are GLP-1 friendly are ways restaurants can acclimate to this new consumer climate.

Refining Food Manufacturing: Reformulate or Reinvent?

The GLP-1 movement signifies a turning point for food brands. To align with this growing group of consumers, CPG manufacturers are strategizing new ways to highlight functional benefits and nutritional content in their products and on their packaging. Emphasizing portion control will be critical, from reformulating offerings into smaller pack sizes to developing single-serve snacking and individually portioned meal options.

Behind the scenes, R&D teams are innovating to stay ahead. Testing new ingredients, exploring sugar alternatives, and modifying wellness messaging around energy, focus, and digestion support rather than weight loss, drives this innovation and defines a new era in what “value” means.

What’s Next?

GLP-1 takers are fueling an industry built on hope, hoping science can finally deliver what willpower alone has not. How consumers think and connect with food altogether is challenging the status quo of dieting.

GLP-1s represent a cultural sign that consumers are redefining what it means to eat well. For the food industry, that means a new level of innovation that rewards smart reformulation, empathetic marketing, and a deeper understanding of evolving appetites.

Food brands that can pivot toward nutrient density, functional ingredients, and value-driven innovation will be best positioned to succeed. For restaurants, flexible offerings, including portion variety, menu transparency, and balanced meal choices, support this changing customer base.

 

 

Are you looking to integrate GLP-1 messaging into your content strategy or new product launches? Do you need support in helping your restaurant customers innovate menus with GLP-1-friendly options?

We can help! Our team of culinarians and operational engagement strategists has simplified the process of concepting, menu research and innovation, sales cuttings, and more for our valuable clients. We’d love to have a conversation to hear your needs.

 

Sources: 1,2Rise of GLP-1 weight loss drugs and consumer health, PWC.com, 2025,  3,4American Medical Association,  5,6GLP-1 Medications Force Food Industry Rethink, IFT, 9-16-25,  7Purdue Agribusiness and AInvest

Connect

Twitter LinkedIn Instagram

Updates In Your In Box

    Published By

    Michelle McMullen

    Michelle brings 20 years of combined food and beverage experience both in client service and content development. Leveraging her expertise in managing teams for clients and overseeing content development led her to her current role of Director, Content Creation. Her passion for crafting compelling content is driven by her immersion in industry insights and consumer behavior data as well as her natural gift for writing, both long and short form.

    View all posts by Michelle McMullen